PHP
MRSN

Parkman Healthcare Partners’s Mersana Therapeutics MRSN Stock Holding History

Parkman Healthcare Partners’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-4,921
Closed -$3.27M – 92
2020
Q4 		$3.27M Sell
4,921
-682
-12% -$379K 0.84% 46
2020
Q3 		$2.61M Sell
5,603
-4,397
-44% -$2.22M 0.69% 50
2020
Q2 		$5.85M Buy
+10,000
New +$3.41M 1.65% 25

Other funds holding MRSN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Parkman Healthcare Partners's MRSN Position: Q1 2021 in Review

Parkman Healthcare Partners sold out of Mersana Therapeutics (MRSN) in Q1 2021, closing a stake of 4,921 shares — an estimated $3.27M sold.

Parkman Healthcare Partners first reported a position in MRSN in Q2 2020 and held it in 3 quarters. The position peaked at $5.85M in Q2 2020. 132 funds tracked by Wall St. Rank hold MRSN as of Q1 2021.

  • Parkman Healthcare Partners reported no remaining Mersana Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Parkman Healthcare Partners sold 4,921 Mersana Therapeutics shares in Q1 2021, an estimated $3.27M.
  • Parkman Healthcare Partners first reported a position in Mersana Therapeutics in Q2 2020 and held it in 3 quarters.
  • Parkman Healthcare Partners's Mersana Therapeutics position peaked at $5.85M in Q2 2020.
  • 132 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q1 2021.

Based on Parkman Healthcare Partners's 13F filing for Q1 2021, filed 14 May 2021.